Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases
Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases
复制标题
DOI：
10.1111/bjh.15921
复制
发表时间：
2019-07-01
影响因子：
6.5
通讯作者：
Galicier, Lionel
中科院分区：
文献类型：
--
作者：
Boutboul, David;Fadlallah, Jehane;Galicier, Lionel
我们回顾性分析了71例单中心性Castleman病，这是一种罕见的，通常无症状的良性淋巴增生性疾病，表现为独特的淋巴结肿块。虽然手术被认为是金标准治疗，但只有38例（54%）患者接受了最初的手术切除，95%的患者治愈。另有9名患者在尝试医疗复位后进行了手术。21例患者采用减量治疗，有效率为55%，但没有最佳方案的证据。由于相关毒性，放疗仅限于8例患者。在13名无症状患者中考虑观察和等待，其中11名患者保持稳定长达17年。
We retrospectively analysed 71 cases of Unicentric Castleman disease, a rare, usually asymptomatic, benign lymphoproliferative disorder presenting as a unique nodal mass. Although surgery is considered as the gold standard therapy, only 38 patients (54%) underwent initial surgical resection and 95% were cured. An additional 9 patients had surgery after an attempt at medical reduction. Reduction therapy was used in 21 patients with a 55% response rate, but without evidence for an optimal regimen. Radiotherapy was limited to 8 patients because of associated toxicity. Watch and wait was considered in 13 asymptomatic patients and 11 of these remained stable for up to 17 years.